Levothyroxine 200 μg (levothyroxine sodium)

1. Description

T4 Levothyroxine 200 mcg is a synthetic formulation of thyroxine (levothyroxine sodium), identical to the endogenous thyroid hormone thyroxine (T4). It is used to replace or supplement endogenous T4 in patients with hypothyroidism, to suppress thyroid‑stimulating hormone (TSH) in selected cases (e.g., differentiated thyroid cancer), and as part of emergency management for severe hypothyroidism (myxedema coma) when given intravenously. Oral 200 mcg tablets represent one of the higher single‑tablet strengths commonly prescribed.

Indications (common)

• Primary or secondary hypothyroidism (replacement therapy).
• Suppression of TSH in differentiated thyroid carcinoma (dose and target TSH individualized).
• Replacement after thyroidectomy or radioactive iodine ablation.
• Part of treatment for myxedema coma (IV route typically used).

Contraindications and cautions

• Uncorrected adrenal insufficiency (replacement with glucocorticoids may be required before or at initiation).
• Acute myocardial infarction, acute thyrotoxicosis—use extreme caution and lower starting doses in patients with significant cardiovascular disease.
• Known hypersensitivity to levothyroxine or excipients.

Always individualize therapy and consult a clinician for diagnosis and dosing.

2. How does T4 Levothyroxine 200 mcg work?

Levothyroxine is a synthetic prohormone (T4). After absorption, peripheral deiodinases convert T4 to the active hormone triiodothyronine (T3) in target tissues. T3 binds to nuclear thyroid hormone receptors and modulates transcription of numerous genes controlling metabolic rate, growth, development, and energy homeostasis. Replacement therapy restores normal metabolic activity in hypothyroid patients. Suppressive doses lower TSH by negative feedback on the hypothalamic–pituitary–thyroid axis.

Pharmacokinetics (brief)

• Oral bioavailability: ~60–80% (variable with formulation and GI factors).
• Peak serum levels typically 2–4 hours after oral dose.
• Half‑life: approximately 7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states).
• Protein bound (~99%); steady state achieved in ~4–6 weeks.

3. Dosage

Important principles

• Individualize dose based on age, weight, cardiac status, pregnancy, concurrent medications, and laboratory monitoring (TSH, free T4).
• When changing dose or formulation, recheck TSH and free T4 about 6–8 weeks after change (earlier if clinical concern).
• Avoid using levothyroxine for weight loss—this is unsafe.

Typical oral replacement dosing (general)

• Full replacement target: approximately 1.6 mcg/kg/day in healthy adults.
  • Example: 70 kg × 1.6 mcg/kg ≈ 112 mcg/day.
• Many adults stabilize on 100–150 mcg/day; 200 mcg/day is used when higher daily replacement is required (e.g., larger body weight, malabsorption, interacting drugs, or after near-total thyroidectomy in some patients).

Starting doses and special populations

• Healthy younger adults with no cardiac disease: may start near estimated replacement (e.g., 1.6 mcg/kg/day) or initiate at 50–100 mcg/day and titrate.
• Older adults or those with coronary artery disease, arrhythmias, or severe hypertension: start low (12.5–25 mcg/day) and increase slowly (every 4–6 weeks) to avoid cardiac ischemia or arrhythmia.
• Patients with subclinical hypothyroidism: small doses (25–50 mcg/day) may be used depending on symptoms and TSH level; treatment individualized.
• Pregnancy: requirements frequently increase (approximately 20–30%); frequently monitor TSH every 4 weeks until stable and again at least once each trimester. Dosing often increased promptly at pregnancy confirmation.
• Pediatrics:
  • Newborns/infants (congenital hypothyroidism): 10–15 mcg/kg/day (higher per kg).
  • Children: 4–6 mcg/kg/day (age-dependent).
• Obesity: dosing based on lean body weight or adjusted body weight rather than total body weight to avoid overdose; consult specialist.
• Renal impairment: does not usually require dose adjustment, but monitor clinically and with labs.

IV dosing (severe hypothyroidism / myxedema coma)

• Typical initial IV bolus: 200–500 mcg IV once (many protocols use 200 mcg).
• Maintenance IV: 50–100 mcg IV daily until oral therapy can be resumed.
• Give stress‑dose glucocorticoids until adrenal insufficiency is excluded.
• Close hemodynamic and cardiac monitoring required.

Switching formulations or brands

• Product bioequivalence is not perfect among all brands/generics. When switching formulations or manufacturers, monitor TSH about 6–8 weeks and adjust dose if needed.

Monitoring and target levels

• Primary hypothyroidism: aim for TSH generally within the laboratory reference range (often 0.4–4.0 mIU/L), with a typical target 0.5–2.5 mIU/L for most patients; individualize by age, pregnancy, and comorbidity.
• TSH suppression for thyroid cancer: target TSH depends on tumor risk stratification; may be <0.1 mIU/L for high‑risk patients under specialist guidance.
• Reassess TSH and clinical status 6–8 weeks after initiation or dose change; once stable, monitor every 6–12 months or more frequently if pregnancy or intercurrent illness/medication changes.

Administration advice

• Take on an empty stomach 30–60 minutes before breakfast OR at bedtime at least 3–4 hours after last meal (consistent timing daily improves absorption).
• Swallow whole with water. Do not crush or chew extended‑release formulations without checking formulation details.
• Space from interfering agents (see interactions): separate by 4 hours from calcium, iron supplements, antacids containing aluminum or magnesium, sucralfate, bile acid sequestrants, and some oral phosphate binders.

Missed dose

• If a dose is missed, take it as soon as remembered the same day. Do not double doses to make up. Resume usual schedule.

Consult a clinician for individual dosing; the numbers above are general guidance only.

4. Side effects

Adverse effects are most commonly related to excessive dosing (iatrogenic hyperthyroidism) or undertreatment.

Signs and symptoms of over‑replacement (hyperthyroid effects)

• Palpitations, tachycardia, atrial fibrillation (particularly in older adults or those with heart disease).
• Nervousness, anxiety, tremor.
• Heat intolerance, sweating, weight loss despite increased appetite.
• Insomnia.
• Increased intestinal motility, diarrhea.
• Menstrual irregularities, decreased fertility.
• Long‑term: accelerated bone loss (osteopenia/osteoporosis), increased fracture risk.

Signs of inadequate replacement (persistent hypothyroid)

• Fatigue, weight gain, cold intolerance.
• Bradycardia, constipation, dry skin, hair loss.
• Slow mentation, depression.
• Elevated serum cholesterol.

Rare but serious adverse reactions

• Cardiac ischemia, myocardial infarction, arrhythmias (especially when dosing is increased rapidly or in patients with underlying cardiac disease).
• Acute adrenal crisis may occur if adrenal insufficiency is unrecognized—consider glucocorticoid coverage if clinically indicated.
• Hypersensitivity or allergic reactions to excipients (rare).
• In susceptible patients (e.g., those with osteoporosis), chronic over‑replacement can cause clinically significant bone loss and fractures.

Drug interactions that affect efficacy or safety (examples)

• Drugs that reduce absorption: calcium, iron salts, antacids (aluminum/ magnesium), sucralfate, bile acid sequestrants, sevelamer, orlistat, some proton pump inhibitors — space dosing by several hours.
• Drugs that increase hepatic metabolism of levothyroxine: rifampin, carbamazepine, phenytoin, phenobarbital — may require dose increase.
• Estrogen therapy, pregnancy, and selective estrogen receptor modulators increase thyroxine‑binding globulin (TBG) and may raise dose requirements.
• Amiodarone and lithium: complex effects on thyroid function; monitor closely.
• Warfarin: initiation or adjustment of levothyroxine can increase anticoagulant effect (increase INR) — monitor more frequently.
• Beta‑blockers, corticosteroids, propylthiouracil (PTU), and amiodarone can reduce peripheral conversion of T4 to T3 — may transiently alter clinical picture.

Report any concerning symptoms (chest pain, palpitations, severe shortness of breath, signs of allergic reaction) to a healthcare provider immediately.

5. Storage

• Store at controlled room temperature, typically 15–30°C (59–86°F). Follow manufacturer labeling; avoid extremes of heat and cold.
• Protect from moisture and light. Keep tablets in their original container/blister pack until use; avoid storing in bathrooms or near sinks where humidity is high.
• Keep out of reach of children and pets. Label expiration date and discard expired medication.
• Do not freeze. If tablets are crushed or repackaged (e.g., into pill organizers), be aware that stability and potency can be affected over time—use caution and consult pharmacist.
• If you have questions about proper storage for a specific brand or formulation, consult the package insert or your pharmacist.

General safety notes

• Use only as prescribed. Regular laboratory monitoring and clinical follow‑up are essential to ensure therapeutic effectiveness and safety.
• Notify clinicians about changes in other medications, pregnancy status, or symptoms suggesting under‑ or over‑replacement.

If you need dosing examples tailored to a particular patient scenario (age, weight, cardiac history, pregnancy, or co‑medications), provide the clinical details and I can outline recommended starting doses and monitoring plans.